Pancreatic Cancer Research

ResearcherVrije Universiteit BrusselActive in the last 2 years

Ilse Rooman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7264-2246; OpenAlex author ID A5047608079. Sources: OpenAlex.

Their work

Papers
25 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
2
Collaborators
78
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: 4 papers · 2015: 3 papers · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 25

  1. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy. Co-author DOI 10.1038/s41416-025-03274-0↗
  2. Current progress in targeting mitotic kinases in PDAC. First author DOI 10.1039/d5md00162e↗
  3. Drug Repurposing in Pancreatic Cancer: A Multi-Stakeholder Perspective to Improve Treatment Options for Pancreatic Cancer Patients. Co-author DOI 10.2147/cmar.s483151↗
  4. High-resolution and quantitative spatial analysis reveal intra-ductal phenotypic and functional diversification in pancreatic cancer. Last author DOI 10.1002/path.6212↗
  5. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Stereotactic Body Radiotherapy Co-author DOI 10.1101/2024.04.30.591890↗
  6. On the Origin of Pancreatic Cancer: Molecular Tumor Subtypes in Perspective of Exocrine Cell Plasticity. Last author DOI 10.1016/j.jcmgh.2021.11.010↗
  7. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  8. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  9. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice. Co-author DOI 10.1136/jitc-2020-001250↗
  10. Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. Last author DOI 10.1093/annonc/mdz181↗
  11. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  12. ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. Co-author DOI 10.15252/emmm.201606743↗
  13. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  14. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  15. SOX9 regulates ERBB signalling in pancreatic cancer development. Co-author DOI 10.1136/gutjnl-2014-307075↗
  16. Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas. Last author DOI 10.2174/1568009615666150512102957↗
  17. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Co-author DOI 10.1002/ijc.28765↗
  18. Chronic pancreatitis: a path to pancreatic cancer. Last author DOI 10.1016/j.canlet.2013.08.015↗
  19. Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development. Co-author DOI 10.1038/onc.2013.312↗
  20. Sirtainties in pancreatic cancer? Co-author DOI 10.18632/oncoscience.28↗
  21. Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer. Last author DOI 10.1158/0008-5472.can-12-3359↗
  22. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Co-author DOI 10.1186/gm482↗
  23. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Co-author DOI 10.1038/nature11547↗
  24. Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development? Co-author DOI 10.1136/gut.2010.235804↗
  25. Retinoid signaling in pancreatic cancer, injury and regeneration. Co-author DOI 10.1371/journal.pone.0029075↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rémy Nicolle · 4 shared papers, 2019–2026 · strength 0.65
  2. Jean‐Luc Van Laethem · 4 shared papers, 2019–2026 · strength 0.65
  3. Christelle Bouchart · 3 shared papers, 2024–2026 · strength 0.55
  4. Tatjana Arsenijevic · 3 shared papers, 2024–2026 · strength 0.55
  5. Thomas M. A. Barlow · 1 shared paper, 2025 · strength 0.42
  6. Steven Ballet · 1 shared paper, 2025 · strength 0.42
  7. Ellis Michiels · 2 shared papers, 2024–2026 · strength 0.39
  8. Julie Navez · 2 shared papers, 2024–2026 · strength 0.38
  9. Léo Mas · 2 shared papers, 2024–2026 · strength 0.38
  10. Pieter Demetter · 2 shared papers, 2024–2026 · strength 0.38
  11. Nicky D’Haene · 2 shared papers, 2024–2026 · strength 0.38
  12. Shulin Zhao · 2 shared papers, 2024–2026 · strength 0.38
  13. Matthieu Hein · 2 shared papers, 2024–2026 · strength 0.38
  14. Oier Azurmendi Senar · 2 shared papers, 2024–2026 · strength 0.38
  15. Kosta Stosic · 2 shared papers, 2024–2026 · strength 0.38
  16. Jean‐Baptiste Bachet · 2 shared papers, 2024–2026 · strength 0.38
  17. Sandrina Martens · 2 shared papers, 2019–2024 · strength 0.27
  18. Andreia V. Pinho · 5 shared papers, 2013–2017 · strength 0.27
  19. Andrew Victor Biankin · 6 shared papers, 2011–2019 · strength 0.25
  20. Claudia Fuchs · 1 shared paper, 2025 · strength 0.20
  21. Alfredo Budillon · 1 shared paper, 2025 · strength 0.20
  22. Violeta V. Stoyanova-Beninska · 1 shared paper, 2025 · strength 0.20
  23. Stephen Bigelsen · 1 shared paper, 2025 · strength 0.20
  24. Alfredo Carrato · 1 shared paper, 2025 · strength 0.20
  25. Luca Cardone · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.